Latest News

Indian shares fall as crude prices rise

Indian shares fall as crude prices rise
Indian shares fall as crude prices rise

Indian?shares dropped in the morning trade of Wednesday as rising 'oil prices' and caution before local and U.S.?inflation?data hit sentiment.

As of 10:05 a.m. IST, the Nifty '50 fell 0.43% to?24366.40, and the BSE Sensex fell 0.42%, dropping to 77827.31.

13 of 16 major sectors posted losses. Small-caps and midcaps both fell by 0.3%.

Sunny Agrawal is the head of fundamental research for SBI Securities. She said, "Market sentiment remains subdued due to elevated crude prices which keep investors cautious."

Oil was hovering around $90 per barrel as the hopes of a possible deal that would bring stability to the Middle East, and reopen the Strait of Hormuz, faded. India is the world's third largest oil importer.

The Nifty Metal Index rose by 0.5% as global aluminium prices reached a seven-week peak?on supply concerns in the Gulf and reduced inventories.

Aluminum producers Hindalco & National Aluminium led the way, with a rise of?2.5% & 7.3% respectively.

State-owned banks increased by 1.8% following a flat closing in the previous session, and a decline of 1.7% on Monday.

Godrej Consumer Products fell nearly 9.4% following the abrupt departure of Sudhir Sitapati as its chief executive just a few months after he was reappointed. The consumer index fell 0.8% as a result.

After the close of the market, domestic?inflation figures could provide clues about how higher crude oil prices and a weaker monsoon will affect?the economy.

The Federal Reserve may make future rate decisions based on the consumer inflation data that will be released later today and the producer price data this week.

Individual stocks like footwear maker Bata India rose?3.5% following a 23% increase in profit year-over-year for the June quarter.

Zydus Lifesciences, a drug?maker, lost 2.6% during the market hours of?Tuesday after it reported a drop in profit for the quarter ending June. The stock gained?6.4% the previous session.

Jefferies flagged U.S. Drug regulator's observations made at a facility as a potential risk to FY2028 earning. (Reporting and editing by Subhranshu Sahu, Harikrishnan Nair and Vivek Kumar M)

(source: Reuters)